When it comes to helping our four-legged pals, San Diego-based Sorrento Therapeutics, Inc. (NASDAQ:SRNE) is always out with new ideas.
Monday, the company announced that review of early results from an on-going “declawed cat pain trial” (run by its Ark Animal Health division) prompted management to assign a high priority to exploring the use of resiniferatoxin as a local nerve block injection for the control of neuropathic post-amputation residual limb pain in humans.
A full IND package is being prepared for submission to the U.S. Food and Drug Administration in the second half this year.
Nine cats that have been living for years with debilitating neuropathic post-declaw pain were included to date in the ongoing ARK clinical trial.
Every cat treated was considered a treatment success at Day 28, regardless of dose group, as defined by FDA Center for Veterinary Medicine guidance using a validated feline pain and behavior scale. No failures noted through Day 120, though, admittedly, only two cats have completed the follow-up visits so far.
Shares in SRNE acquired a dime, or 3.4%. to $3.05, on volume of 464,000